Who is sponsoring NCT01572519?

NCT01572519 is sponsored by Janssen Research & Development, LLC.

What drugs are being tested in NCT01572519?

Interventions in NCT01572519: Phase 1, Cohort 1, Phase 1, Cohort 2, Phase 1, Cohort 3, Phase 1, Cohort 4, Phase 2.

What condition does NCT01572519 study?

NCT01572519 studies Relapsed or Refractory Hodgkin Lymphoma.

Is NCT01572519 still recruiting?

NCT01572519 is currently completed. Last updated 20 November 2020.

Last reviewed 2020-11-20 · How we verify

NCT01572519

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma

Completed Phase 1 Last updated 20 November 2020

What this trial tests

Phase 1 trial testing Phase 1, Cohort 1 in Relapsed or Refractory Hodgkin Lymphoma in 21 participants. Completed in 13 August 2013.

Timeline

17 July 2012

Primary endpoint
13 August 2013

13 August 2013

Quick facts

Lead sponsor	Janssen Research & Development, LLC
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	17 July 2012
Primary completion	13 August 2013
Estimated completion	13 August 2013
Sites	4 locations across France, Germany

Drugs / interventions tested

Phase 1, Cohort 1 — full drug profile →
Phase 1, Cohort 2
Phase 1, Cohort 3
Phase 1, Cohort 4
Phase 2

Conditions studied

Relapsed or Refractory Hodgkin Lymphoma — all drugs for Relapsed or Refractory Hodgkin Lymphoma →

Sponsor

Janssen Research & Development, LLC — full company profile →

Who can join

18 and older, any sex, with Relapsed or Refractory Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the safety, pharmacokinetics, and preliminary efficacy information of JNJ-40346527 in patients with relapsed or refractory Hodgkin lymphoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.
Cannarile MA, Weisser M, Jacob W, Jegg AM, et al · · 2017 · cited 796× · PMID 28716061 · DOI 10.1186/s40425-017-0257-y
Research trends in pharmacological modulation of tumor-associated macrophages.
Wang N, Wang S, Wang X, Zheng Y, et al · · 2021 · cited 88× · PMID 33463063 · DOI 10.1002/ctm2.288
Targeting of TAMs: can we be more clever than cancer cells?
Kzhyshkowska J, Shen J, Larionova I. · · 2024 · cited 79× · PMID 39516356 · DOI 10.1038/s41423-024-01232-z
Functionalized Nanoparticles Targeting Tumor-Associated Macrophages as Cancer Therapy.
He Y, de Araújo Júnior RF, Cruz LJ, Eich C. · · 2021 · cited 48× · PMID 34683963 · DOI 10.3390/pharmaceutics13101670
Small-molecule agents for cancer immunotherapy.
Wang F, Fu K, Wang Y, Pan C, et al · · 2024 · cited 41× · PMID 38486980 · DOI 10.1016/j.apsb.2023.12.010
CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies.
Abdin SM, Paasch D, Morgan M, Lachmann N. · · 2021 · cited 28× · PMID 34462325 · DOI 10.1136/jitc-2021-002741
NK Cell Anti-Tumor Surveillance in a Myeloid Cell-Shaped Environment.
Russo E, Laffranchi M, Tomaipitinca L, Del Prete A, et al · · 2021 · cited 26× · PMID 34975880 · DOI 10.3389/fimmu.2021.787116
Targeting tumor-associated macrophages to reverse antitumor drug resistance.
Li S, Sheng J, Zhang D, Qin H. · · 2024 · cited 9× · PMID 38787372 · DOI 10.18632/aging.205858

Verify or expand the search:

Other recruiting trials for Relapsed or Refractory Hodgkin Lymphoma

Currently open trials in the same condition.

NCT05896046 — SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma · Phase 1, PHASE2 · recruiting

Other Janssen Research & Development, LLC trials

Trials by the same sponsor.

NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
NCT07309445 — A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC · recruiting
NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01572519 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Research & Development, LLC
Last refreshed: 20 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01572519.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing